Wealthquest Corp has strategically expanded its portfolio by acquiring a substantial new stake in Select Medical Holdings Corporation, a significant move for the health services provider. This initial acquisition, totaling 8,563 shares valued at approximately $143,000, marks a notable entry point for the firm into the healthcare stocks sector.
Beyond Wealthquest Corp, a multitude of other prominent hedge funds and institutional investors have also recently adjusted their positions in Select Medical, indicating widespread activity in the company’s stock market presence. LPL Financial LLC, for instance, modestly increased its stake, signaling continued confidence in the company’s trajectory.
Further illustrating the trend of institutional investment, Vista Finance LLC significantly bolstered its holdings, demonstrating a growing interest in Select Medical’s performance. Similarly, Net Worth Advisory Group and Bank of Montreal Can each incrementally raised their stakes, contributing to the evolving ownership landscape of the health services firm.
The financial health of Select Medical Holdings Corporation remains a focal point for investors, with the company boasting a market capitalization of $1.62 billion. Its robust financial metrics, including a P/E ratio of 11.86 and a PEG ratio of 0.79, suggest a stable and potentially undervalued entity within the healthcare stocks industry.
In a strategic move to enhance shareholder value, Select Medical’s Board of Directors has approved a substantial share repurchase program, authorizing the buyback of up to $1.00 billion in shares. This aggressive initiative, which could reacquire a significant portion of its stock, often signals management’s belief that shares are currently trading below their intrinsic value.
Demonstrating a commitment to its shareholders, the company recently announced a quarterly dividend payout, set to be distributed on August 28th. This consistent return to investors, coupled with a dividend yield of 2.0%, underscores the company’s financial stability and attractiveness to income-focused portfolios.
Adding to the dynamic market analysis, recent insider activity also caught the attention of investors, with a director acquiring a considerable block of shares. This direct purchase, valued at over $315,000, reflects a strong vote of confidence from within the company’s leadership and significantly increased the director’s total holdings.
Research analysts have actively weighed in on Select Medical’s prospects, with multiple firms issuing “outperform” and “buy” ratings. Despite some target price adjustments, the consensus among analysts remains a “Moderate Buy,” with an average price target that suggests potential upside, reinforcing the company’s position as a noteworthy institutional investment.
